Screener
Immunome IMNM Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 5,492 | 2,996 |
| Net loss | $(53,839) | $(41,640) |
| Net loss per share, basic and diluted | $(0.48) | $(0.52) |
| Weighted-average shares outstanding, basic and diluted | 113,136,836 | 79,410,354 |
| Comprehensive loss: | ||
| Net loss | $(53,839) | $(41,640) |
| Unrealized loss on marketable securities | — | (60) |
| Comprehensive loss | $(53,839) | $(41,700) |
Item 1. Financial Statements.
FAQ
- What is Immunome's shares (diluted)?
- Immunome (IMNM) reported shares (diluted) of 113.1M in Q1 2026.
- How has Immunome's shares (diluted) changed year-over-year?
- Immunome's shares (diluted) increased by 42.5% year-over-year, from 79.4M to 113.1M.
- What is the long-term trend for Immunome's shares (diluted)?
- Over 4 years (2021 to 2025), Immunome's shares (diluted) has grown at a 65.5% compound annual growth rate (CAGR), from 45.6M to 341.7M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Immunome's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude